首页> 外文期刊>Frontiers in Pediatrics >Heterozygous Mutation in Adenosine Deaminase Gene in a Patient With Severe Lymphopenia Following Corticosteroid Treatment of Autoimmune Hemolytic Anemia
【24h】

Heterozygous Mutation in Adenosine Deaminase Gene in a Patient With Severe Lymphopenia Following Corticosteroid Treatment of Autoimmune Hemolytic Anemia

机译:糖皮质激素治疗自身免疫性溶血性贫血后严重淋巴细胞减少症患者腺苷脱氨酶基因的杂合突变

获取原文
获取外文期刊封面目录资料

摘要

We describe a previously healthy 14-year-old girl with acute onset autoimmune hemolytic anemia, associated with severe but transient lymphopenia during corticosteroid therapy, without infectious episodes during follow-up. After detailed investigations to rule out an underlying immunodeficiency, we detected a heterozygous ADA gene mutation. This was associated with slightly increased blood levels of adenosine and deoxyadenosine nucleotides and with reduced ADA activity in red blood cells, but within the normal range. This observation suggests that heterozygous ADA mutation might be a predisposing factor for lymphopenia in patients receiving corticosteroid therapy.
机译:我们描述了一个先前健康的14岁女孩,患有急性发作的自身免疫性溶血性贫血,在皮质类固醇治疗期间与严重但短暂的淋巴细胞减少症相关,在随访期间无感染性发作。经过详细调查以排除潜在的免疫缺陷后,我们检测到杂合的ADA基因突变。这与血液中腺苷和脱氧腺苷核苷酸水平略有增加以及红细胞中ADA活性降低有关,但均在正常范围内。该观察结果表明,杂合性ADA突变可能是接受皮质类固醇治疗的患者发生淋巴细胞减少的诱因。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号